Zacks Research Brokers Reduce Earnings Estimates for HALO

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Stock analysts at Zacks Research decreased their Q4 2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a note issued to investors on Monday, November 24th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $1.76 for the quarter, down from their prior estimate of $1.88. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q1 2026 earnings at $1.17 EPS.

Several other brokerages also recently commented on HALO. The Goldman Sachs Group raised their price objective on shares of Halozyme Therapeutics from $54.00 to $56.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 18th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Benchmark lifted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Finally, JMP Securities boosted their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research report on Wednesday, August 6th. Seven analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $75.10.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $72.66 on Thursday. Halozyme Therapeutics has a 52-week low of $46.26 and a 52-week high of $79.50. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The business’s 50 day moving average price is $69.46 and its two-hundred day moving average price is $63.66. The firm has a market cap of $8.54 billion, a PE ratio of 16.63, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. During the same quarter in the prior year, the company earned $1.27 EPS. The firm’s revenue for the quarter was up 22.1% compared to the same quarter last year.

Insider Activity

In other news, Director Bernadette Connaughton sold 4,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the completion of the sale, the director directly owned 46,952 shares of the company’s stock, valued at $3,459,423.36. The trade was a 7.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $50,721,994.47. The trade was a 2.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 110,227 shares of company stock worth $8,028,955 over the last three months. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of HALO. CWM LLC lifted its stake in Halozyme Therapeutics by 46.3% during the 1st quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 438 shares in the last quarter. AE Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics in the first quarter valued at about $206,000. LPL Financial LLC raised its holdings in shares of Halozyme Therapeutics by 17.1% in the first quarter. LPL Financial LLC now owns 242,432 shares of the biopharmaceutical company’s stock valued at $15,470,000 after purchasing an additional 35,429 shares during the last quarter. Mackenzie Financial Corp lifted its position in shares of Halozyme Therapeutics by 392.1% during the first quarter. Mackenzie Financial Corp now owns 85,609 shares of the biopharmaceutical company’s stock valued at $5,463,000 after purchasing an additional 68,213 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new position in Halozyme Therapeutics during the first quarter worth about $89,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.